SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules CIV) is available for a low cash price in more than 70,000 retail pharmacy locations nationwide exclusively via GoodRx.

加利福尼亚州圣莫尼卡（商业新闻短讯）--美国领先的处方储蓄平台GoodRx（纳斯达克：GDRX）今天宣布，QSYMIA®（芬太明和托吡酯缓释胶囊CIV）仅通过GoodRx在全国70000多家零售药店以低现金价格提供。

This initiative not only propels GoodRx’s momentum in weight loss solutions, but also broadens its portfolio in offering significant savings on brand-name medications, making obesity treatment more accessible and affordable for millions..

这一举措不仅推动了GoodRx在减肥解决方案方面的势头，而且扩大了其在品牌药物方面的投资组合，使数百万人更容易获得和负担得起肥胖治疗。。

According to the CDC, more than two in five U.S. adults have obesity, and untreated obesity increases the risk of type 2 diabetes, hypertension, heart disease, and mortality. While demand for weight-loss medications has soared in recent years, consumers often struggle to access them due to high costs and lack of insurance coverage.

根据疾病预防控制中心的数据，超过五分之二的美国成年人患有肥胖症，未经治疗的肥胖症会增加患2型糖尿病、高血压、心脏病和死亡率的风险。虽然近年来对减肥药物的需求激增，但由于成本高且缺乏保险，消费者往往难以获得减肥药物。

By making QSYMIA more accessible, GoodRx and Vivus are helping those struggling with weight and obesity find more affordable ways to access the treatments they need..

通过使QSYMIA更容易获得，GoodRx和Vivus正在帮助那些与体重和肥胖症作斗争的人找到更实惠的方法来获得他们所需的治疗。。

Now, anyone with a valid prescription, regardless of insurance status, can use GoodRx to purchase a 30-day supply of QSYMIA at the exclusive cash price of $149. QSYMIA is designed to help patients manage hunger and reduce cravings throughout the day and, combined with a healthy diet and exercise, has been proven to help patients lose and maintain weight.

现在，任何持有有效处方的人，无论其保险状况如何，都可以使用GoodRx以149美元的独家现金价格购买30天的QSYMIA。QSYMIA旨在帮助患者控制饥饿，减少全天的渴望，并结合健康的饮食和锻炼，已被证明可以帮助患者减肥和维持体重。

Many individuals prefer oral medications over injectables, and the simplicity of taking a daily pill can make it easier to adhere to treatment regimens..

许多人更喜欢口服药物而不是注射剂，每天服用避孕药的简单性可以更容易地坚持治疗方案。。

“Obesity medications are life-changing for millions of Americans, but accessibility and affordability are often a barrier for many consumers,” said Dorothy Gemmell, Chief Commercial Officer at GoodRx. “Through this partnership, we’re making headway in getting these critical medications into the hands of those who need them and improving access to a medication that not only helps with weight loss, but is also tied to better outcomes for other costly chronic diseases.”.

GoodRx首席商务官多萝西·杰梅尔（DorothyGemmell）说：“肥胖药物正在改变数百万美国人的生活，但对许多消费者来说，可获得性和可负担性往往是一个障碍。”。。

“We are dedicated to expanding access to our critical medications that consumers rely on,” said John Amos, CEO at VIVUS. “Collaborating with GoodRx enables us to offer an affordable solution for individuals who have prescriptions for QSYMIA and expand access to those seeking a cost-effective option to fill them.

VIVUS首席执行官约翰·阿莫斯（JohnAmos）表示：“我们致力于扩大消费者依赖的关键药物的获取渠道。”。“与GoodRx的合作使我们能够为有QSYMIA处方的个人提供负担得起的解决方案，并扩大那些寻求成本效益高的选择来填补他们的机会。

One in five adults and one in four young adults (12-17) experience weight loss on the top dose of QSYMIA of at least 20% of their body weight. Our partnership with GoodRx coupled with the weight loss profile of QSYMIA offers Americans an unprecedented value vs. other therapies.”.

五分之一的成年人和四分之一的年轻人（12-17岁）在服用QSYMIA的最高剂量时体重减轻了至少20%。我们与GoodRx的合作关系以及QSYMIA的减肥概况为美国人提供了前所未有的价值，而不是其他疗法。”。

GoodRx works with nearly 150 brands across pharmaceutical manufacturers, medical device companies and OTC medicines to surface their savings and patient support programs directly with high-intent audiences via the GoodRx platform. The company recently announced a partnership with Pfizer to offer its menopause hormone therapies at low prices in retail pharmacies exclusively via GoodRx.

GoodRx与制药商、医疗器械公司和OTC药品的近150个品牌合作，通过GoodRx平台直接向高意向受众展示他们的储蓄和患者支持计划。该公司最近宣布与辉瑞公司合作，专门通过GoodRx在零售药店以低价提供更年期激素疗法。

Similarly, the company launched an affordability program with ARS Pharmaceuticals to offer neffy at an exclusive low discounted cash price in retail pharmacies across the U.S..

类似地，该公司与ARS Pharmaceuticals推出了一项可负担性计划，在美国各地的零售药店以独家低折扣现金价格向neffy提供服务。。

About GoodRx

关于GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information.

GoodRx是美国领先的处方储蓄平台。GoodRx每年受到2500多万消费者和750000名医疗保健专业人员的信任。GoodRx在全国70000多家药店提供仿制药和名牌药物的储蓄和可负担性选择，以及全面的医疗保健研究和信息。

Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions..

自2011年以来，GoodRx帮助消费者节省了超过750亿美元的处方费用。。

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts.

GoodRx定期在其投资者关系网站上发布对投资者可能重要的信息https://investors.goodrx.com.我们打算将我们的网站用作披露重大非公开信息的手段，并遵守FD法规规定的披露义务。因此，鼓励投资者和潜在投资者定期访问GoodRx的网站以获取重要信息，此外，还应关注GoodRx的新闻稿、向证券交易委员会（“SEC”）提交的文件以及公开电话会议和网络广播。

The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release..

GoodRx网站上包含的或可通过GoodRx网站访问的信息未通过引用纳入本新闻稿，也不属于本新闻稿的一部分。。

About VIVUS

关于VIVUS

VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit http://www.vivus.com.

VIVUS是一家生物制药公司，致力于创新疗法的开发和商业化，专注于为严重未满足医疗需求的患者推进治疗。有关该公司的更多信息，请访问http://www.vivus.com.

About QSYMIA

关于QSYMIA

QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition..

QSYMIA与减少卡路里饮食和增加体力活动相结合，以减少12岁及以上肥胖的成年人和儿科患者以及超重的成年人的超重，并长期保持体重减轻。至少有一种与体重相关的合并症。。

The effect of QSYMIA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSYMIA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

QSYMIA对心血管疾病发病率和死亡率的影响尚未确定。QSYMIA与其他减肥产品（包括处方药，非处方药和草药制剂）联合使用的安全性和有效性尚未确定。

For more information on QSYMIA, please visit https://QSYMIA.com/

有关QSYMIA的更多信息，请访问https://QSYMIA.com/

Important Safety Information for QSYMIA

Do not take QSYMIA if you are pregnant, planning to become pregnant, or become pregnant during QSYMIA treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days; are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in QSYMIA..

如果您怀孕，计划怀孕或在QSYMIA治疗期间怀孕，请不要服用QSYMIA；患有青光眼；有甲状腺问题（甲状腺功能亢进）；正在服用某些称为单胺氧化酶抑制剂（MAOIs）的药物或在过去14天内服用了MAOIs；对托吡酯、拟交感神经胺（如芬特明）或QSYMIA中的任何成分过敏。。

QSYMIA can cause serious side effects, including birth defects (cleft lip/cleft palate), serious eye problems (secondary angle closure glaucoma), visual field defects (independent of elevated intraocular pressure), suicidal thoughts or actions, and severe rash with blisters and peeling skin. QSYMIA may slow the increase in height in children 12 years and older..

QSYMIA可引起严重的副作用，包括出生缺陷（唇裂/腭裂），严重的眼部问题（继发性闭角型青光眼），视野缺陷（与眼压升高无关），自杀念头或行为，以及严重的皮疹伴水疱和皮肤脱落。QSYMIA可能会减缓12岁及以上儿童的身高增长。。

Common side effects of QSYMIA in adults include numbness or tingling in the hands, arms, feet, or face (paraesthesia), dizziness, changes in the way foods taste or loss of taste (dysgeusia), trouble sleeping (insomnia), constipation, and dry mouth. Common side effects of Qsymia in children aged 12 years and older include depression, dizziness, joint pain, fever, flu, and ankle sprain..

成人QSYMIA的常见副作用包括手，臂，脚或脸麻木或刺痛（感觉异常），头晕，食物味道改变或味觉丧失（味觉障碍），睡眠困难（失眠），便秘和口干。Qsymia对12岁及以上儿童的常见副作用包括抑郁、头晕、关节疼痛、发烧、流感和脚踝扭伤。。

For more information please read the Qsymia Medication Guide, Full Prescribing Information, and Risk of Birth Defects with Qsymia patient brochure.

有关更多信息，请阅读Qsymia药物指南，完整的处方信息以及Qsymia患者手册中的出生缺陷风险。

GoodRx Forward-Looking Statements

GoodRx前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings and accessibility; and the objectives and potential benefits and value of the GoodRx and Vivus partnership.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。本新闻稿中包含的所有与历史事实无关的声明均应视为前瞻性声明，包括但不限于有关预期消费者储蓄和可及性的声明；以及GoodRx和Vivus合作伙伴关系的目标、潜在利益和价值。

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause GoodRx’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to GoodRx’s ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, GoodRx’s reliance on a limited number of industry participants, and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2023, and GoodRx’s other filings with the Securities and Exchange Commission.

这些声明既不是承诺也不是保证，而是涉及已知和未知的风险、不确定性和其他重要因素，这些风险、不确定性和其他重要因素可能会导致GoodRx的实际结果、业绩或成就与前瞻性声明明示或暗示的任何未来结果、业绩或成就有实质性差异，包括但不限于与GoodRx实现广泛市场教育和改变消费者购买习惯的能力有关的风险、药品定价和定价结构的变化、GoodRx对有限数量的行业参与者的依赖、GoodRx截至2023年12月31日的10-K年度报告中题为“风险因素”的部分以及GoodRx在证券和外汇委员会。

Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While GoodRx may elect to update such forward-looking statements at some point in the future, GoodRx disclaims any obligation to do so, even if subsequent events cause GoodRx’s views to change..

任何此类前瞻性声明均基于截至本新闻稿发布之日的当前预期、预测和估计。虽然GoodRx可能会选择在未来某个时候更新此类前瞻性声明，但GoodRx不承担任何义务，即使后续事件导致GoodRx的观点发生变化。。